Glenmede Trust’s Aerie Pharmaceuticals AERI Stock Holding History

Glenmede Trust’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,854	Closed	-$33K	–	2440
2020 Q3	$33K	Buy	2,854 +169	+6%	+$2.06K	﹤0.01%	1440
2020 Q2	$39K	Sell	2,685 -1,339	-33%	-$19.8K	﹤0.01%	1378
2020 Q1	$97K	Hold	4,024	–	–	﹤0.01%	1431
2019 Q4	$97K	Buy	4,024 +528	+15%	+$10.9K	﹤0.01%	1431
2019 Q3	$67	Buy	3,496 +736	+27%	+$16.9K	﹤0.01%	1542
2019 Q2	$81	Sell	2,760 -2,420	-47%	-$93.2K	﹤0.01%	1480
2019 Q1	$246	Buy	5,180 +1,605	+45%	+$70.6K	﹤0.01%	1105
2018 Q4	$128	Sell	3,575 -2,088	-37%	-$98K	﹤0.01%	1283
2018 Q3	$348K	Buy	5,663 +1,787	+46%	+$115K	﹤0.01%	981
2018 Q2	$262K	Buy	3,876 +3,162	+443%	+$177K	﹤0.01%	989
2018 Q1	$42K	Hold	714	–	–	﹤0.01%	1700
2017 Q4	$42K	Buy	+714	New	+$43.3K	﹤0.01%	1700

Other funds holding AERI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Glenmede Trust's AERI Position: Q4 2020 in Review

Glenmede Trust sold out of Aerie Pharmaceuticals (AERI) in Q4 2020, closing a stake of 2,854 shares — an estimated $33K sold.

Glenmede Trust first reported a position in AERI in Q4 2017 and held it in 12 quarters. The position peaked at $348K in Q3 2018. 150 funds tracked by Wall St. Rank hold AERI as of Q4 2020.

Glenmede Trust reported no remaining Aerie Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Glenmede Trust sold 2,854 Aerie Pharmaceuticals shares in Q4 2020, an estimated $33K.
Glenmede Trust first reported a position in Aerie Pharmaceuticals in Q4 2017 and held it in 12 quarters.
Glenmede Trust's Aerie Pharmaceuticals position peaked at $348K in Q3 2018.
150 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.